Kelong Han, Ph.D.
Affiliations: | 2010 | University of Pittsburgh, Pittsburgh, PA, United States |
Area:
PharmacyGoogle:
"Kelong Han"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Raman Venkataramanan | grad student | 2010 | University of Pittsburgh | |
| (Clinical Pharmacokinetics and Population Pharmacokinetic Analysis of Voriconazole in Transplant Patients.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Han K, Chanu P, Jonsson F, et al. (2016) Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer. The Aaps Journal |
| Han K, Peyret T, Marchand M, et al. (2016) Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemotherapy and Pharmacology |
| Han K, Jin JY, Marchand M, et al. (2015) Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology |
| Han K, Peyret T, Quartino A, et al. (2015) Bevacizumab dosing strategy in pediatric cancer patients based on population pharmacokinetic analysis with external validation. British Journal of Clinical Pharmacology |
| Pillai VC, Han K, Beigi RH, et al. (2015) Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women. British Journal of Clinical Pharmacology |
| Han K, Ren M, Wick W, et al. (2015) Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma. Neuro-Oncology. 17: 764-5 |
| Eppler S, Gordon MS, Redfern CH, et al. (2015) Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors. Anti-Cancer Drugs. 26: 448-55 |
| Han K, Jin J, Maia M, et al. (2014) Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. The Aaps Journal. 16: 1056-63 |
| Claret L, Gupta M, Han K, et al. (2014) Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab. Journal of Clinical Pharmacology. 54: 253-7 |
| Han K, Peyret T, Gosselin NH, et al. (2014) Similar exposure and pharmacokinetics of bevacizumab in pediatric and adult cancer patients: Analysis of individual data of 152 pediatric patients. Journal of Clinical Oncology. 32: 10062-10062 |